AIHA in antiphospholipid syndrome: what it means for APS patients
Official title: Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome
Run by New Valley University · NCT07743242 · Data updated 2026-11-12
This study tests how autoimmune hemolytic anemia affects people with antiphospholipid syndrome and what it means for their risk of clots and organ problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 230 (estimated) |
| Sponsor | New Valley University Academic / other |
| Locations | 1 site (Al Khārjah, Kharga Oasis) |
| Status | Recruiting |
| Started | June 5, 2026 |
| Main results expected | November 30, 2027 |
| Study ends | April 15, 2028 |
| Registry record updated | August 10, 2026 |
| Trial ID | NCT07743242 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with confirmed antiphospholipid syndrome who also have anemia consistent with autoimmune hemolysis.
✕Probably not a fit
Patients without autoimmune hemolytic anemia or those without APS–related anemia may not benefit from findings focused on AIHA in APS.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional project investigates the clinical implications of autoimmune hemolytic anemia in adults with antiphospholipid syndrome. Enrollment focuses on adults with anemia due to autoimmune hemolysis and confirmed APS, with hemoglobin/Coombs testing as part of the assessment. The study aims to describe thrombosis risk, organ involvement, and outcomes to better understand how AIHA coexists with APS. Hematologic parameters and standard APS characteristics will be collected to correlate with clinical events. Lead oversight is by New Valley University, at the Khārjah and Kharga Oasis sites.
Why it matters
Potential benefit: If successful, the study could clarify how AIHA influences APS-related complications, guiding risk stratification and management.
How similar studies have gone: Previous observations suggest AIHA occurs with higher thrombotic risk in APS, but systematic characterization is limited, making this approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥18 years * Patients with anemia consistant with hemolysis. * Patient diagnosed with antiphospholipid syndrome. * Informed consent obtained Exclusion Criteria: * Age less than 18 years. * Other causes of anemia than autoimmune hemolysis.
Where it's running
-
New Valley University
Al Khārjah, Kharga Oasis, Egypt Recruiting
Study contacts
- Study coordinator: Asmaa N Hussein, MD
- Email: asmaanady_1010@med.nvu.edu.eg
- Phone: 01065161752
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
National cohort for patients with antiphospholipid syndrome in China
This study is trying to learn more about antiphospholipid syndrome by following 2,000 patients in China with positive antiphospholipid antibodies to see how it affects their health over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.